T2 Alpha Femur Antegrade PF

Brief description of study

This investigation is a prospective, multicenter clinical investigation designed to examine the safety and efficacy/performance of the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System. Over the past decades, femoral nailing has become the treatment of choice for most femoral fractures. As an addition to the femoral nails, Stryker has created a new generation femoral implant, the T2 Alpha Femur Antegrade Piriformis Fossa (PF) Nail. This device is not an experimental medical device and is approved by the United States Food and Drug Administration (FDA).


Clinical Study Identifier: s18-01615
ClinicalTrials.gov Identifier: NCT04015154
Principal Investigator: Nirmal C Tejwani.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.